Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Efficacy and safety of mildronate for acute ischemic stroke: a randomized, double-blind, active-controlled phase II multicenter trial.

Zhu Y, Zhang G, Zhao J, Li D, Yan X, Liu J, Liu X, Zhao H, Xia J, Zhang X, Li Z, Zhang B, Guo Z, Feng L, Zhang Z, Qu F, Zhao G.

Clin Drug Investig. 2013 Oct;33(10):755-60. doi: 10.1007/s40261-013-0121-x.

PMID:
23949899
2.

Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial.

Li B, Wang Y, Lu J, Liu J, Yuan Y, Yu Y, Wang P, Zhao X, Wang Z.

Trials. 2015 Dec 9;16:561. doi: 10.1186/s13063-015-1076-4.

3.

The effect of Ginkgo biloba on functional outcome of patients with acute ischemic stroke: a double-blind, placebo-controlled, randomized clinical trial.

Oskouei DS, Rikhtegar R, Hashemilar M, Sadeghi-Bazargani H, Sharifi-Bonab M, Sadeghi-Hokmabadi E, Zarrintan S, Sharifipour E.

J Stroke Cerebrovasc Dis. 2013 Nov;22(8):e557-63. doi: 10.1016/j.jstrokecerebrovasdis.2013.06.010. Epub 2013 Jul 18.

PMID:
23871729
4.

[The efficacy of the mildronate treatment of patients with ischemic stroke].

Vinichuk SM.

Vrach Delo. 1991 Jul;(7):77-9. Russian.

PMID:
1771844
5.

Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1).

Lampl Y, Zivin JA, Fisher M, Lew R, Welin L, Dahlof B, Borenstein P, Andersson B, Perez J, Caparo C, Ilic S, Oron U.

Stroke. 2007 Jun;38(6):1843-9. Epub 2007 Apr 26.

6.

Efficacy and safety of ginsenoside-Rd for acute ischaemic stroke: a randomized, double-blind, placebo-controlled, phase II multicenter trial.

Liu X, Xia J, Wang L, Song Y, Yang J, Yan Y, Ren H, Zhao G.

Eur J Neurol. 2009 May;16(5):569-75. doi: 10.1111/j.1468-1331.2009.02534.x. Epub 2009 Feb 19.

PMID:
19236467
7.

[Efficacy and safety of mildronate in emergency medical care].

Nevzorov NM, Markevich YN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(9 Pt 2):33-42. Russian.

PMID:
24107893
8.

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.

Elkins J, Veltkamp R, Montaner J, Johnston SC, Singhal AB, Becker K, Lansberg MG, Tang W, Chang I, Muralidharan K, Gheuens S, Mehta L, Elkind MSV.

Lancet Neurol. 2017 Mar;16(3):217-226. doi: 10.1016/S1474-4422(16)30357-X. Epub 2017 Feb 15.

PMID:
28229893
9.

Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial.

Shyu WC, Lin SZ, Lee CC, Liu DD, Li H.

CMAJ. 2006 Mar 28;174(7):927-33. Epub 2006 Mar 3.

10.

Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.

Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators.

Stroke. 2012 Mar;43(3):630-6. doi: 10.1161/STROKEAHA.111.628537. Epub 2012 Jan 26.

11.

DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke.

Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G.

Stroke. 2008 Jun;39(6):1774-8. doi: 10.1161/STROKEAHA.107.506378. Epub 2008 Apr 10.

12.

TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke.

Kraglund KL, Mortensen JK, Grove EL, Johnsen SP, Andersen G.

Int J Stroke. 2015 Aug;10(6):985-7. doi: 10.1111/ijs.12485. Epub 2015 Apr 8.

PMID:
25854537
13.

The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.

Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group.

Stroke. 2005 Jan;36(1):66-73. Epub 2004 Nov 29.

14.

CHInese Medicine NeuroAiD Efficacy on Stroke Recovery - Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy.

Venketasubramanian N, Young SH, Tay SS, Umapathi T, Lao AY, Gan HH, Baroque AC 2nd, Navarro JC, Chang HM, Advincula JM, Muengtaweepongsa S, Chan BP, Chua CL, Wijekoon N, de Silva HA, Hiyadan JH, Suwanwela NC, Wong KS, Poungvarin N, Eow GB, Lee CF, Chen CL; CHIMES-E Study Investigators.

Cerebrovasc Dis. 2015;39(5-6):309-18. doi: 10.1159/000382082. Epub 2015 Apr 22.

15.

NXY-059 for the treatment of acute ischemic stroke.

Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U; SAINT II Trial Investigators.

N Engl J Med. 2007 Aug 9;357(6):562-71.

16.

Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.

Torgano G, Zecca B, Monzani V, Maestroni A, Rossi P, Cazzaniga M, Manganaro D, Boiti C, Zilioli E, Borutti G, Falaschi F, Mandelli C.

Cerebrovasc Dis. 2010 Feb;29(3):275-81. doi: 10.1159/000275503. Epub 2010 Jan 15.

PMID:
20090319
18.

A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.

Adeoye O, Knight WA, Khoury J, Schmit PA, Sucharew H, Broderick JP, Pancioli AM; CLEAR-ER Investigators.

J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):e313-5. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.012. Epub 2014 Feb 15.

19.

The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.

Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, del Zoppo G, Kleindorfer D, Woo D, Khatri P, Castaldo J, Frey J, Gebel J Jr, Kasner S, Kidwell C, Kwiatkowski T, Libman R, Mackenzie R, Scott P, Starkman S, Thurman RJ; CLEAR Trial Investigators.

Stroke. 2008 Dec;39(12):3268-76. doi: 10.1161/STROKEAHA.108.517656. Epub 2008 Sep 4.

Supplemental Content

Support Center